World Journal of Gastroenterology,
Год журнала:
2023,
Номер
29(2), С. 257 - 271
Опубликована: Янв. 5, 2023
The
new
coronavirus
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
was
identified
in
December
2019,
Wuhan,
China.
virus
rapidly
spread
worldwide,
causing
disease
2019
(COVID-19)
pandemic.
Although
COVID-19
is
presented,
usually,
with
typical
symptoms
(i.e.,
dyspnea,
cough)
and
fever,
extrapulmonary
manifestations
are
also
encountered.
Liver
injury
a
common
feature
patients
ranges
from
mild
temporary
elevation
of
liver
enzymes
to
and,
even,
failure.
pathogenesis
damage
not
clearly
defined;
multiple
mechanisms
contribute
disorder,
including
direct
cytopathic
viral
effect,
cytokine
storm
immune-mediated
hepatitis,
hypoxic
injury,
drug-induced
toxicity.
Patients
underlying
chronic
cirrhosis,
non-alcoholic
fatty
disease,
alcohol-related
hepatocellular
carcinoma,
etc.)
may
have
greater
risk
develop
both
further
deterioration,
as
consequence,
certain
issues
should
be
considered
during
management.
aim
this
review
present
the
prevalence,
clinical
manifestation
pathophysiological
SARS-CoV-2
infection.
Moreover,
we
overview
association
between
infection
briefly
discuss
management
COVID-19.
Liver International,
Год журнала:
2020,
Номер
41(1), С. 20 - 32
Опубликована: Ноя. 15, 2020
The
recent
outbreak
of
coronavirus
disease
2019
(COVID-19),
caused
by
the
Severe
Acute
Respiratory
Syndrome
Coronavirus-2
(SARS-CoV-2)
has
resulted
in
a
world-wide
pandemic.
Disseminated
lung
injury
with
development
acute
respiratory
distress
syndrome
(ARDS)
is
main
cause
mortality
COVID-19.
Although
liver
failure
does
not
seem
to
occur
absence
pre-existing
disease,
hepatic
involvement
COVID-19
may
correlate
overall
severity
and
serve
as
prognostic
factor
for
ARDS.
spectrum
range
from
direct
infection
SARS-CoV-2,
indirect
systemic
inflammation,
hypoxic
changes,
iatrogenic
causes
such
drugs
ventilation
exacerbation
underlying
disease.
This
concise
review
discusses
potential
pathophysiological
mechanisms
SARS-CoV-2
tropism
well
possibly
long-term
Alimentary Pharmacology & Therapeutics,
Год журнала:
2020,
Номер
52(4), С. 584 - 599
Опубликована: Июль 8, 2020
Summary
Background
The
incidence
of
elevated
liver
chemistries
and
the
presence
pre‐existing
chronic
disease
(CLD)
have
been
variably
reported
in
COVID‐19.
Aims
To
assess
prevalence
CLD,
outcomes
patients
with
without
underlying
CLD/elevated
Methods
A
comprehensive
search
electronic
databases
from
1
December
2019
to
24
April
2020
was
done.
We
included
studies
reporting
CLD
or
patient
Results
107
articles
(n
=
20
874
patients)
were
for
systematic
review.
pooled
3.6%
(95%
CI,
2.5‐5.1)
among
15
407
COVID‐19
patients.
23.1%
(19.3‐27.3)
at
initial
presentation.
Additionally,
24.4%
(13.5‐40)
developed
during
illness.
drug‐induced
injury
25.4%
(14.2‐41.4).
1587
severely
infected
3.9%
(3%‐5.2%).
odds
developing
severe
0.81
(0.31‐2.09;
P
0.67)
compared
non‐CLD
had
increased
risk
mortality
(OR‐3.46
[2.42‐4.95,
<
0.001])
(OR‐2.87
[95%
2.29‐3.6,
chemistries.
Conclusions
Elevated
are
common
presentation
severity
correlates
outcome
does
not
alter
Further
needed
analyse
compensated
decompensated
disease.
PLoS ONE,
Год журнала:
2021,
Номер
16(5), С. e0250602 - e0250602
Опубликована: Май 3, 2021
Objective
We
aimed
to
systematically
identify
the
possible
risk
factors
responsible
for
severe
cases.
Methods
searched
PubMed,
Embase,
Web
of
science
and
Cochrane
Library
epidemiological
studies
confirmed
COVID-19,
which
include
information
about
clinical
characteristics
severity
patients’
disease.
analyzed
potential
associations
between
Results
identified
a
total
41
eligible
including
21060
patients
with
COVID-19.
Severe
cases
were
potentially
associated
advanced
age
(Standard
Mean
Difference
(SMD)
=
1.73,
95%
CI:
1.34–2.12),
male
gender
(Odds
Ratio
(OR)
1.51,
CI:1.33–1.71),
obesity
(OR
1.89,
1.44–2.46),
history
smoking
1.40,
CI:1.06–1.85),
hypertension
2.42,
2.03–2.88),
diabetes
2.40,
1.98–2.91),
coronary
heart
disease
(OR:
2.87,
2.22–3.71),
chronic
kidney
(CKD)
2.97,
1.63–5.41),
cerebrovascular
(
OR
2.47,
1.54–3.97),
obstructive
pulmonary
(COPD)
2.88,
1.89–4.38),
malignancy
2.60,
2.00–3.40),
liver
1.06–2.17).
Acute
respiratory
distress
syndrome
(ARDS)
39.59,
19.99–78.41),
shock
21.50,
10.49–44.06)
acute
injury
(AKI)
8.84,
4.34–18.00)
most
likely
prevent
recovery.
In
summary,
conditions
had
higher
rate
comorbidities
complications
than
non-severe
conditions.
Conclusion
Patients
who
male,
age,
obesity,
smoking,
hypertension,
diabetes,
malignancy,
disease,
COPD,
or
CKD
are
more
develop
COVID-19
symptoms.
ARDS,
AKI
thought
be
main
hinderances
Phytotherapy Research,
Год журнала:
2021,
Номер
35(5), С. 2616 - 2623
Опубликована: Янв. 3, 2021
Curcumin
is
proposed
as
a
potential
treatment
option
for
coronavirus
disease-19
(COVID-19)
by
inhibiting
the
virus
entrance,
encapsulation
and
replication,
modulating
various
cellular
signaling
pathways.
In
this
open-label
nonrandomized
clinical
trial,
efficacy
of
nano-curcumin
oral
formulation
has
been
evaluated
in
hospitalized
patients
with
mild-moderate
COVID-19.
Forty-one
who
fulfilled
inclusion
criteria
were
allocated
to
(n
=
21)
group
(Sinacurcumin
soft
gel,
contains
40
mg
curcuminoids
nanomicelles,
two
capsules
twice
day)
or
control
20)
group,
2
weeks.
Patients'
symptoms
laboratory
data
assessed
at
baseline
during
follow-up
period.
Most
including
fever
chills,
tachypnea,
myalgia,
cough
resolved
significantly
faster
curcumin
group.
Moreover,
SaO2
was
higher
after
2,
4,
7,
14
days
lymphocyte
count
7
days.
Duration
supplemental
O2
use
hospitalization
also
meaningfully
shorter
It
noteworthy
mention
that
no
patient
experienced
deterioration
infection
period,
but
it
occurred
40%
Oral
nano-formulation
can
improve
recovery
time
COVID-19
patients.
Further
randomized
placebo
controlled
trials
larger
sample
size
are
recommended.
Viruses,
Год журнала:
2023,
Номер
15(1), С. 175 - 175
Опубликована: Янв. 7, 2023
The
clinical
course
and
outcome
of
COVID-19
are
highly
variable,
ranging
from
asymptomatic
infections
to
severe
disease
death.
Understanding
the
risk
factors
is
relevant
both
in
setting
at
epidemiological
level.
Here,
we
provide
an
overview
host,
viral
environmental
that
have
been
shown
or
(in
some
cases)
hypothesized
be
associated
with
outcomes.
considered
detail
include
age
frailty,
genetic
polymorphisms,
biological
sex
(and
pregnancy),
co-
superinfections,
non-communicable
comorbidities,
immunological
history,
microbiota,
lifestyle
patient;
variation
infecting
dose;
socioeconomic
factors;
air
pollution.
For
each
category,
compile
(sometimes
conflicting)
evidence
for
association
factor
outcomes
(including
strength
effect)
outline
possible
action
mechanisms.
We
also
discuss
complex
interactions
between
various
factors.
Severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)
has
spread
to
many
countries
around
the
world.
In
addition
lung
disease,
severe
cases
also
displayed
varying
degrees
of
liver
injury.
This
article
will
describe
latest
developments
regarding
coronavirus
and
pathogenesis
injury,
prone
population
clinical
characteristics
these
patients,
as
well
providing
some
suggestions
for
treatment.
Liver International,
Год журнала:
2021,
Номер
41(10), С. 2404 - 2417
Опубликована: Май 21, 2021
Little
is
known
about
cholestasis,
including
its
most
severe
variant
secondary
sclerosing
cholangitis
(SSC),
in
critically
ill
patients
with
coronavirus
disease
19
(COVID-19).
In
this
study,
we
analysed
the
occurrence
of
cholestatic
liver
injury
and
SSC,
clinical,
serological,
radiological
histopathological
findings.We
conducted
a
retrospective
single-centre
analysis
all
consecutive
admitted
to
intensive
care
unit
(ICU)
as
result
COVID-19
at
University
Hospital
Zurich
describe
these
patients.
The
findings
were
compared
cohort
influenza
A.A
total
34
ICU
included.
Of
these,
14
(41%)
had
no
cholestasis
(group
0),
11
(32%,
group
1)
developed
mild
9
(27%,
2)
cholestasis.
Patients
2
more
complicated
course
indicated
by
significantly
longer
stay
(median
51
days,
IQR
25-86.5)
than
other
groups
0:
median
9.5
3.8-18.3,
P
=
.001;
1:
16
8-30,
<
.05
respectively).
Four
SSC
none
A
cohort.
available
suggest
an
ischaemic
damage
perihilar
bile
ducts.The
development
represents
important
complication
needs
be
considered
diagnostic
work
up
prolonged
interest
ongoing
pandemic
since
it
associated
considerable
morbidity
mortality.
Digestive and Liver Disease,
Год журнала:
2020,
Номер
53(2), С. 146 - 152
Опубликована: Сен. 16, 2020
The
coronavirus
pandemic
has
changed
the
priorities
of
whole
medical
society.
During
clinical
course
COVID-19,
it
been
observed
that
hepatic
injury
occurs
in
a
significant
proportion
patients,
particularly
those
with
severe
or
critical
illness.
In
this
literature
review,
we
summarize
most
recent
studies,
which
covered
pathophysiology
COVID-19
induced
liver
including;
pathological
findings,
therapy
related
damage,
and
effects
viral
infection
on
pre-existing
diseasesin
context
recommendations.
Conclusions:
This
review
sheds
light
impact
liver,
as
well
prognostic
effect
laboratory
markers
disease
outcome.
Temporal
variations
parameters
during
different
patterns
derangement
are
depicted.
More
intensive
surveillance
individualized
therapeutic
approaches
should
be
tailored
for
immunocompromised
patients
advanced
disease,
hepatocellular
carcinoma,
transplant
patients.
Despite
limited
studies
infected
preexisting
comprehensive
overview
provides
perspective
management
COVID-19.
Hepatology,
Год журнала:
2020,
Номер
74(2), С. 1088 - 1100
Опубликована: Дек. 18, 2020
Infection
with
the
severe
acute
respiratory
syndrome
coronavirus
2
(SARS‐CoV‐2),
a
novel
that
emerged
in
late
2019,
is
posing
an
unprecedented
challenge
to
global
health.
Coronavirus
disease
2019
(COVID‐19),
clinical
caused
by
SARS‐CoV‐2,
has
variable
presentation
ranging
from
asymptomatic
infection
life‐threatening
distress
and
multiorgan
failure.
Liver
involvement
common
during
COVID‐19
exhibits
spectrum
of
manifestations
elevations
liver
function
tests
hepatic
decompensation.
The
presence
abnormal
been
associated
more
overall
mortality.
Although
SARS‐CoV‐2
RNA
detected
patients
COVID‐19,
it
remains
unclear
whether
productively
infects
replicates
cells
direct
liver‐pathogenic
effect.
cause
injury
can
be
attributed
multiple
factors,
including
virus‐induced
systemic
inflammation,
hypoxia,
congestion,
drug‐induced
disease.
Among
cirrhosis,
decompensation
liver‐related
Additionally,
COVID‐19’s
impact
on
health
care
resources
adversely
affect
delivery
outcomes
chronic
Understanding
underlying
mechanisms
will
important
management
especially
those
advanced
This
review
summarizes
our
current
knowledge
virus‐host
interactions
as
well
COVID‐19.
Pathogens,
Год журнала:
2021,
Номер
10(5), С. 565 - 565
Опубликована: Май 7, 2021
The
pathogenesis
of
coronavirus
disease
2019
(COVID-19),
caused
by
severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
is
still
not
fully
unraveled.
Though
preventive
vaccines
and
treatment
methods
are
out
on
the
market,
a
specific
cure
for
has
been
discovered.
Recent
investigations
research
studies
primarily
focus
immunopathology
disease.
A
healthy
immune
system
responds
immediately
after
viral
entry,
causing
immediate
annihilation
recovery.
However,
an
impaired
causes
extensive
systemic
damage
due
to
unregulated
response
characterized
hypersecretion
chemokines
cytokines.
elevated
levels
cytokine
or
hypercytokinemia
leads
distress
(ARDS)
along
with
multiple
organ
damage.
Moreover,
against
SARS-CoV-2
linked
race,
gender,
age;
hence,
this
infection's
outcome
differs
among
patients.
Many
therapeutic
strategies
focusing
immunomodulation
have
tested
assuage
storm
in
patients
COVID-19.
thorough
understanding
diverse
signaling
pathways
triggered
virus
essential
before
contemplating
relief
measures.
This
present
review
explains
interrelationships
hyperinflammatory
severity.
Furthermore,
we
thrown
light
mechanisms
risk
factors
that
influence
molecular
lead
infection
Recognition
altered
dysregulated
can
be
loophole
identify
potential
target
markers.
Identifying
biomarkers
pathway
aid
better
clinical
management
COVID-19
special
also
given
potent
inhibitors
proinflammatory
cytokines,
immunomodulatory
immunotherapeutic
options
ameliorate
inflammatory
responses
affected